Mechanisms of Lactylation-Driven Metabolic Reprogramming in Cancer

Abstract

Lactylation, a recently characterized post-translational modification, has emerged as a pivotal regulator of cellular metabolism and gene expression in cancer. This review explores the mechanisms by which lactylation modulates metabolic reprogramming, influencing tumor progression, adaptation, and therapeutic resistance. Integrating current PubMed-indexed research and clinical implications, the article elucidates the interplay between lactate metabolism, histone lactylation, and oncogenic pathways, highlighting its relevance for oncologists and clinical scientists.

Introduction

Cancer metabolism has undergone a paradigm shift with the discovery of novel post-translational modifications, such as lactylation, that link altered metabolic states with epigenetic regulation. Lactylation, primarily catalyzed by the accumulation of lactate under hypoxic and glycolytic conditions, modifies lysine residues on histones and non-histone proteins, thereby influencing gene transcription and cellular phenotypes. Understanding the mechanisms of lactylation-driven metabolic reprogramming is crucial for developing targeted therapies and improving clinical outcomes in oncology.

Epidemiology / Disease Burden

Cancer remains a leading cause of morbidity and mortality globally, with metabolic dysregulation being a hallmark of virtually all malignancies. The prevalence of metabolic reprogramming, particularly the Warburg effect (aerobic glycolysis), is observed in over 80% of solid tumors, underscoring the clinical relevance of lactylation as a metabolic-epigenetic link. Epidemiological studies indicate that tumors with high glycolytic activity exhibit increased lactylation, correlating with aggressive phenotypes and poorer prognoses across diverse cancer types, including breast, lung, and colorectal cancers.

Pathophysiology

The pathophysiological basis of lactylation-driven metabolic reprogramming stems from cancer cells reliance on glycolysis, even in the presence of oxygen. This generates excessive lactate, which is exported to the tumor microenvironment and taken up by stromal or immune cells, perpetuating a pro-tumorigenic milieu. Intracellularly, lactate acts as a substrate for histone lactylation, mediated by enzymes such as p300/CBP. This modification alters chromatin accessibility and gene expression, promoting the transcription of genes involved in cell proliferation, angiogenesis, and immune evasion. The dynamic crosstalk between lactylation and other epigenetic marks, such as acetylation and methylation, further amplifies oncogenic signaling and epigenetic plasticity.

Risk Factors

Risk factors for enhanced lactylation activity in cancer include hypoxia, high tumor glycolytic rates, mutations in metabolic enzymes (e.g., IDH1/2, LDH-A), and oncogenic signaling pathways (e.g., PI3K/AKT/mTOR). Environmental factors such as obesity, diabetes, and chronic inflammation also exacerbate lactate production and lactylation. Genomic instability and tumor heterogeneity contribute to variable lactylation patterns, influencing responses to therapy and disease progression.

Clinical Features

Lactylation-driven metabolic reprogramming is clinically associated with rapid tumor growth, enhanced metastatic potential, resistance to apoptosis, and immunosuppressive tumor microenvironments. Patients may present with aggressive disease phenotypes, therapy resistance, and frequent recurrence. The presence of high lactylation signatures can correlate with advanced tumor stage, poor differentiation, and unfavorable survival rates, particularly in triple-negative breast cancer, glioblastoma, and pancreatic adenocarcinoma.

Diagnosis

Current diagnostic approaches for lactylation involve proteomic and epigenomic analyses, including mass spectrometry, chromatin immunoprecipitation sequencing (ChIP-seq), and immunohistochemistry using lactylation-specific antibodies. Biomarker development is ongoing, with efforts to correlate lactylation profiles with clinical outcomes and therapeutic response. Non-invasive metabolic imaging (e.g., hyperpolarized MRI) and circulating tumor DNA (ctDNA) assays may offer future avenues for monitoring lactylation dynamics in vivo.

Treatment & Management

Therapeutic strategies targeting lactylation-driven metabolic reprogramming include inhibitors of glycolysis (e.g., 2-deoxyglucose), lactate transporters (MCT1/4 inhibitors), and histone acetyltransferases (p300/CBP inhibitors). Immune checkpoint inhibitors and metabolic modulators are being investigated for synergistic effects. Personalized medicine approaches that incorporate lactylation status may optimize patient selection and improve responses to targeted therapies. Supportive care measures, including metabolic interventions and nutritional counseling, are integral to comprehensive management.

Recent Advances / Emerging Therapies

Recent research has illuminated the therapeutic potential of directly targeting lactylation machinery. Small-molecule inhibitors of p300/CBP have demonstrated preclinical efficacy in reducing tumor growth and reversing immunosuppression. CRISPR/Cas9-based models have enabled the dissection of lactylation-regulated gene networks, uncovering novel vulnerabilities in cancer stem cells. Combination therapies integrating metabolic and immune modulators are under investigation in early-phase clinical trials. Additionally, the role of lactylation in shaping the tumor immune landscape has spurred interest in developing immunometabolic interventions.

Guideline Recommendations

Although formal guidelines specific to lactylation-targeted therapy are not yet established, leading oncological societies recommend metabolic profiling as part of precision oncology. Incorporating lactylation markers into clinical trials is encouraged to elucidate predictive and prognostic value. Multidisciplinary tumor boards should consider metabolic-epigenetic mechanisms when evaluating therapeutic options, particularly for refractory or relapsed malignancies. Ongoing research will inform future consensus statements and best practice guidelines.

Conclusion

Lactylation-driven metabolic reprogramming represents a paradigm shift in our understanding of cancer biology, linking metabolic flux to epigenetic remodeling and tumor adaptation. Integrating lactylation profiling into clinical practice holds promise for improved prognostication and targeted intervention. Continued translational research and clinical validation are essential to harness the full potential of lactylation-targeted therapies, ultimately enhancing patient outcomes in oncology.